17:47 , May 11, 2018 |  BC Week In Review  |  Clinical News

Mirati reports updated Phase II data for sitravatinib, Opdivo combo

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 23 evaluable non-small cell lung cancer (NSCLC) patients who experienced disease progression following prior treatment with a checkpoint inhibitor in a Phase II trial showing that once-daily oral...
16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine , Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are...
01:20 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinitis Rat studies suggest transplants of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) sheets could help treat retinitis pigmentosa. The sheets were generated by culturing hESC-derived RPEs on a human amniotic membrane...
00:53 , Dec 21, 2017 |  BC Extra  |  Preclinical News

Researchers develop hESC-derived RPE cell sheet

In a paper published in Science Translational Medicine , researchers from Institut National de la Santé et de la Recherche Médicale (INSERM) and colleagues developed a technique to grow human stem cell-derived retinal pigment epithelial...
20:18 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Mirati reports partial responses in Phase II NSCLC trial of sitravatinib

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported preliminary data from a Phase II trial showing that sitravatinib (MGCD516) in combination with PD-1 mAb Opdivo nivolumab led to 3 confirmed partial responses in 11 evaluable patients with non-squamous...
21:25 , Sep 15, 2017 |  BC Extra  |  Clinical News

Mirati, Loxo gain on RET inhibitor presentations

Mirati Therapeutics Inc. (NASDAQ:MRTX) jumped $6.45 (136%) to $11.20 on Friday after reporting Phase II data for its Ret proto-oncogene (RET) inhibitor sitravatinib (MGCD516), making it the second company this week to see its stock...
01:03 , Jan 28, 2017 |  BioCentury  |  Strategy

MER-made

Dong-A ST Co. Ltd. has spent the last four years building an R&D organization and using its chemistry chops to begin developing first-in-class drug candidates against genetically validated targets. A December cancer immunotherapy deal with...
23:15 , Dec 30, 2016 |  BC Extra  |  Company News

Dong-A grants AbbVie rights to MERTK inhibitor

Dong-A ST Co. Ltd. (KSE:170900) granted AbbVie Inc. (NYSE:ABBV) exclusive rights outside South Korea to a c-Mer proto-oncogene tyrosine kinase (MERTK) inhibitor that is in preclinical development to treat cancer. The Korean biotech deferred questions...
21:58 , Dec 30, 2016 |  BC Week In Review  |  Company News

Dong-A ST, AbbVie deal

Dong-A granted AbbVie exclusive, worldwide rights, excluding South Korea, to an undisclosed c-Mer proto-oncogene tyrosine kinase (MERTK) inhibitor, which is in preclinical development to treat cancer. Dong-A ST will receive $40 million up front and...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Xetrios, Kolltan deal

Kolltan acquired Xetrios for an undisclosed amount. Kolltan said it gains IP covering human therapeutics targeting the TAM receptor tyrosine kinase family, including AXL receptor tyrosine kinase (AXL; UFO); c-Mer proto-oncogene tyrosine kinase (MERTK) ;...